

Executive Summary

Introduction

Drug-diagnostic co-development: from concept to reality

New pathways and regulatory change

Strategies for drug-diagnostic co-development in pharma R&D

Stakeholder perspectives on regulatory change: outlook for pharma and diagnostics

About the Authors

Sara Sleigh

Cheryl L Barton

Disclaimer

Introduction

Summary

Introduction

Regulatory framework for drugs and diagnostics in the US

Biomarker guidance

Drug-diagnostic co-development guidance

FDA organization

Drug and biologics regulation by the FDA

Diagnostics regulation by the FDA

Regulatory framework for drugs and diagnostics in the EU

EMA guidance for personalized medicine

Drug and biologics regulation by the EMA

Diagnostics regulation in the EU

Comparing and contrasting regulation in the EU and US: drivers for change

Report outline

Drug-diagnostic co-development: from concept to reality

Summary

Biomarkers and companion diagnostics in drug development

Stages of drug-diagnostic co-development

Biomarker discovery

Analytical validation

Clinical validation and clinical utility

Regulatory approvals of drugs and companion diagnostic tests

Drug-diagnostic co-development: Selzentry

Introducing companion diagnostic tests for efficacy post-approval

Omapro (Chemgenex): a case study

Introducing companion diagnostics for safety reasons

Labeling considerations

Conclusions

New pathways and regulatory change

Summary

Introduction

Biomarker qualification

Biomarker qualification: FDA

Biomarker qualification: EMA

FDA guidance on drug-diagnostic co-development
FDA-industry discussion of the drug-diagnostic co-development concept paper
New FDA guidance documents relating to co-development
Changes to device regulations in the US
Changes at the FDA
Proposed legislative changes
EMA guidance on drug-diagnostic co-development
Changes to device regulations in the EU
Conclusions

Strategies for drug-diagnostic co-development in pharma R&D

Summary
Introduction
Partnership for a specific drug-diagnostic co-development programs
Broad partnership: the preferred provider route
Licensing
In-house diagnostics development
The widening role of CROs
Conclusions

Stakeholder perspectives on regulatory change: outlook for pharma and diagnostics

Summary
Introduction
Regulators
Pharma industry
Diagnostics industry
Patients
Physicians
Payers
Emerging stakeholders
Pharmacy benefit managers
Next generation sequencing companies
Health IT companies
Conclusions and outlook

Appendix

Research methodology
Acknowledgements
Abbreviations
Glossary
References